Introduction
============

*Klebsiella pneumoniae* is an opportunistic pathogen responsible for up to 10% of all nosocomial infections and one of the leading causes of urinary, respiratory and blood infections particularly in immuno-compromised patients ([@b2-bjm-44-849]; [@b19-bjm-44-849]). Emergence and spread of multidrug resistant *K. pneumoniae*, specifically the extended spectrum β-lactamase (ESBL) producing strains, is often responsible for the failure of antibiotic treatment in hospital settings ([@b18-bjm-44-849]). Mobile genetic elements such as plasmids and transposons are reported to carry genetic units named integrons which contain genes for site-specific recombination, and are capable of capturing and mobilizing gene cassettes ([@b10-bjm-44-849]; [@b22-bjm-44-849]). These can be subdivided into two main groups, the superintegrons and the antibiotic resistance integrons (ARIs) ([@b3-bjm-44-849]; [@b8-bjm-44-849]). Dissemination of antibiotic resistance genes among bacteria can occur by mobile genetic elements containing the ARIs ([@b3-bjm-44-849]; [@b11-bjm-44-849]; [@b10-bjm-44-849]). Among different classes of ARIs, classes 1, 2, and 3 have been historically implicated with multiple antibiotic resistance (MAR) phenotypes and are defined based on their respective integrase (*intI*) genes ([@b3-bjm-44-849]; [@b11-bjm-44-849]). Class 1 integrons are the most widespread and have been frequently found in ESBL producing clinical isolates of *Enterobacteriaceae* including *K. pneumoniae* ([@b12-bjm-44-849]; [@b15-bjm-44-849]; [@b21-bjm-44-849]; [@b24-bjm-44-849]). Class 2 integrons occur less frequently in ESBL producing *E. coli* and *K. pneumoniae* and finally, class 3 integrons are rarely found in ESBL producing *K. pneumoniae* ([@b1-bjm-44-849]; [@b5-bjm-44-849]; [@b16-bjm-44-849]). We investigated the antimicrobial susceptibility and prevalence of class 1, 2 and 3 integrons in ESBL producing clinical isolates of *K. pneumoniae* from Iranian patients. The variable regions of class 1 integrons were also detected. Finally, the association between integron carriage and MAR phenotypes were determined.

Materials and Methods
=====================

Bacterial isolates
------------------

One hundred and four clinical isolates of *K. pneumoniae* were collected from hospitalized patients in two teaching hospitals in Tehran (Imam Hussein and Labbafinejad) from March 2008 to March 2009. The majority of the isolates were from urine (n = 90; 86.5%) followed by wound (n = 4; 3.84%), trachea (n = 4; 3.84%), sputum (n = 2; 1.92%), blood (n = 2; 1.92) and other unknown sources (n = 2; 1.92%). The ATCC standard strains *K. pneumoniae* (ATCC 10031) and *E. coli* (ATCC 25922) were used as susceptibility controls. *Klebsiella pneumoniae* (ATCC 1029*)* was kindly provided by Dr. Rajabnia (Babol University, Medical School) for use as positive control for class 1 integron in PCR tests.

ESBL production
---------------

The isolates were initially screened for ESBL production by the double disc synergy test (DDST) using cefotaxime (30 μg), ceftazidime (30 μg) and cefepime (30 μg) placed 20 mm center to center from an amoxicillin/clavulanic acid disk (20/10 μg) (Himedia, India). ESBL production was detected when synergy was observed between the inhibition zones of cephalosporins and amoxicillin/clavulanic acid and was further confirmed by the phenotypic confirmatory test (PCT) using ceftazidime and cefotaxime alone or in combination with clavulanic acid ([@b4-bjm-44-849]; [@b6-bjm-44-849]).

Antimicrobial susceptibility
----------------------------

In vitro antimicrobial susceptibility of ESBL producing isolates was determined to 17 antibiotics according to the CLSI criteria ([@b4-bjm-44-849]). The antimicrobial discs (Himedia, India) were; cefepime (30 μg), ceftazidime (30 μg), cefotaxime (30 μg), imipenem (10 μg), gentamicin (10 μg), tobramycin (10 μg), aztreonam (30 μg), amikacin (30 μg), nitrofurantoin (300 μg), streptomycin (10 μg), spectinomycin (100 μg), norfloxacin (10 μg), kanamycin (30 μg), ampicilin/sulbactam (10/10 μg), colistin (10 μg), co-amoxiclav (20/10 μg), piperacilin (100 μg) and pipercilin/tazobactam (100/10 μg).

Detection of class 1, 2 and 3 integrons by PCR
----------------------------------------------

Isolates were grown overnight (18 h) in Luria Bertani (LB) broth (Difco, Detroit, MI, USA) at 37 °C and genomic DNA was extracted using High Pure PCR template Prep kit for Genomic DNA extraction (Roche Diagnostics, Mannheim, Germany). PCR amplification of classes 1, 2 and 3 integrase genes was performed in 25 μL reaction mixtures containing 30 ng DNA template, 0.4 mM of each dNTP, 150 μM MgCl~2~, 0.2 U Super Taq DNA polymerase (CinnaGen, Tehran, Iran) and 1 pM of each primer (FazaBiotech, Tehran, Iran) as follows: *Int1*F; CCTCCCGCACGATGATC, Int1R; TCCACGCATCGT CAGGC, Int2F; TTATTGCTGGGATTAGGC, Int2R; ACGGCTACCCTCTGTTATC, Int3F; AGTGGGTGGC GAATGAGTG, Int3R; TGTTCTTGTATCGGCAGGTG) ([@b9-bjm-44-849]). Amplifications were performed in a Bioer TC25/HH Thermal Cycler (Bioer Technology Co. Ltd, Hangzhou, China) using the following program: initial denaturation at 95 °C for 5 min followed by 35 cycles of 1 min at 94 °C, 1 min at 60 °C and 1 min at 72 °C with a final extension at 72 °C for 10 min. For the class 1 integron carrying isolates, PCR amplification of variable regions was performed in 20 μL reaction mixtures containing 30 ng DNA template, 20 μM of each dNTP, 150 μM MgCl~2~, 0.2 U Super Taq DNA polymerase and 1 pM of each primer (5′-CS; GGCATCCAAGCAGCAAG, 3′-CS AAGCAGA CTTGACCTGA) ([@b14-bjm-44-849]). Amplification of the integron variable regions was carried out with initial denaturation of 4 min at 94 °C followed by 35 cycles of 1 min at 94 °C, 1 min at 55 °C and 1 min at 72 °C with a final extension of 10 min at 72 °C. The amplified PCR products were resolved by electrophoresis in 1% agarose gels and visualized after staining with ethidium bromide.

Statistical analysis
--------------------

To compare the antibiotic resistance profiles between integron positive and integron negative isolates, non-parametric analysis was performed using the two-tailed Mann-Whitney U test allowing for continuous variable and non-normal distribution.

Results
=======

Among the 104 *K. pneumoniae* clinical isolates, 50 (48%) were confirmed to produce ESBL. The antibiotic susceptibility results showed that all ESBL producing isolates were resistant to piperacillin. Resistance rate to other antibiotics were: amoxiclav (96%), aztreonam, kanamycin and cefotaxime (68%), tobramycin (66%), ceftazidime (64%), ampicillin/sulbactam (60%), spectinomycin (56%), cefepime (52%), norfloxacin (48%), gentamicin (36%), nitrofurantoin (24%), amikacin (22%), piperacillin/tazobactam (20%), colistin (14%) and streptomycin (10%). All isolates were susceptible to imipenem ([Table 1](#t1-bjm-44-849){ref-type="table"}).

PCR amplifications for classes 1 and 2 integrase genes showed that 22 (44%) of the ESBL producing *K. pneumoniae* isolates harbored class 1 ([Figure 1A](#f1-bjm-44-849){ref-type="fig"}) and 3 (6%) carried class 2 integrons ([Figure 1B](#f1-bjm-44-849){ref-type="fig"}), two of which had both classes. None of the isolates carried class 3 integron. Class 1 integron harboring isolates possessed one to three DNA sequences manifested as nine different sized amplicons in the range of 0.5 to 3 kb ([Figure 2](#f2-bjm-44-849){ref-type="fig"}). The integron harboring isolates were significantly more resistant to aminoglycosides including kanamycin (43.2%) and tobramycin (30.7%). The same trend was observed for other antibiotics where integron carrying isolates were more resistant to cefotaxime (43.3%), ceftazidime (42.6%), aztreonam (51.3%), norfloxcacin (32%), cefepime (24.6%) and spectinomycin (25.6%) ([Table 1](#t1-bjm-44-849){ref-type="table"}). On the other hand, resistance to streptomycin and nitrofurantoin was significantly higher in integron negative isolates (p ≤ 0.05) ([Table 1](#t1-bjm-44-849){ref-type="table"}). The association between integron carriage and antibiotic resistance was most significant for aztreonam (p = 0.000) followed by cefotaxime (p ≤ 0.001), kanamycin, ceftazidime and streptomycin (p ≤ 0.01) and finally tobramycin (p ≤ 0.05) ([Table 1](#t1-bjm-44-849){ref-type="table"}). Comparison of MAR phenotype (resistance to 6 or more antibiotics) in the two groups of isolates showed that integron harboring strains had a much higher rate of MAR (95.65%) compared to integron negative isolates (48.15%) (p = 0.000). There was no significant association between the type of specimen with ESBL production, antibiotic susceptibility or integron carriage. However, isolates with similar profiles for class 1 integron variable regions had the same antibiotic resistance phenotypes ([Table 2](#t2-bjm-44-849){ref-type="table"}).

Discussion
==========

ESBL producing *K. pneumoniae* have been reported to harbor higher rates of class 1 integrons compared to non-ESBL strains ([@b1-bjm-44-849]; [@b9-bjm-44-849]; [@b12-bjm-44-849]; [@b15-bjm-44-849]; [@b17-bjm-44-849]; [@b21-bjm-44-849]; [@b23-bjm-44-849]; [@b24-bjm-44-849]). In the current study, 44% of the ESBL positive isolates carried class 1 integrons. We found a significant association between integron carriage and higher rates of resistance to β-lactams and aminoglycosides. Other reports have shown that resistance gene cassettes to all aminoglycosides are carried by class 1 integrons ([@b3-bjm-44-849]; [@b8-bjm-44-849]).

The size range of the amplified fragments for class 1 integron variable regions indicates presence of one or more gene cassettes, providing a possible explanation for various MAR phenotypes, or more than one integron in an isolate. It may also be concluded that these isolates either contain more than one class1 integron with a variety of integrated gene cassettes or integrons which have undergone possible rearrangements ([@b14-bjm-44-849]). Identical antibiotic resistance phenotypes in the isolates carrying similar sized fragments in variable regions could mean that amplicons of the same size carry the same resistance gene cassettes ([@b7-bjm-44-849]).

According to our results, 6% of the ESBL positive isolates harbored class 2 integrons similar to the report by Bhattacharjee *et al.* ([@b1-bjm-44-849]). Several studies have reported restricted distribution of class 2 integrons among the family *Enterobacteriaceae* including *Escherichia coli*, *Salmonella*, *Enterobacter cloacae* and also in *Acinetobacter baumannii* ([@b9-bjm-44-849]; [@b20-bjm-44-849]). To our knowledge, there is only one other report describing class 2 integron in ESBL producing *K. pneumoniae* ([@b1-bjm-44-849]).

We did not find any significant concordance between the presence of the ARIs and a specific MAR phenotype. However, in the integron positive isolates, the frequency of resistance to seven antibiotics from five classes was significantly higher than integron negative strains (p \< 0.05). In addition, integron positive isolates were significantly more likely to show MAR phenotypes than integron negative isolates (p = 0.000). It could be concluded that ARI carriage may at least be partially responsible for not only higher rates of resistance to several antibiotics, but also higher prevalence of MAR phenotypes in *K. pneumoniae* isolates ([@b17-bjm-44-849]; [@b24-bjm-44-849]).

Interestingly, there was an inverse association between resistance to streptomycin and nitrofurantoin with integron carriage, where integron negative isolates were more resistant to these antibiotics. No relationship was found between resistance to amikacin and colistin with integron carriage. Martinez-Freijo and colleagues also found no significant association between presence of integrons and amikacin resistance ([@b17-bjm-44-849]). Similar observations have been made by White and colleagues regarding amikacin and nitrofurantoin ([@b23-bjm-44-849]). These results suggest that resistance to nitrofurantoin and amikacin are independent of resistance gene cassettes carried by ARIs.

Irrespective of whether or not resistance genes are contained within the integrons, the results presented here indicate wide dissemination of ARIs in ESBL producing *K. pneumoniae* and correlation of integron carriage with increased drug resistance rates as well as multidrug resistance. Presence of integron associated resistance in the community has been shown to be widespread and can contribute to multidrug resistance in hospital settings ([@b13-bjm-44-849]). It has been suggested that screening for ARIs could complement existing antibiotic resistance surveillance programs by providing information on resistance profiles as well as dissemination of resistance between commensal and infectious strains ([@b12-bjm-44-849]).
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![PCR amplification product of class 1 (A) and class 2 (B) integrase genes in a number of ESBL producing *Klebsiella pneumoniae* clinical isolates. Ladder, DNA molecular weight marker (100 bp, Fermentas); C+, positive control for class 1 integron; C^−^, negative control (no DNA template).](bjm-44-849-g001){#f1-bjm-44-849}

![PCR amplification of class 1 integron variable regions in ESBL producing *Klebsiella pneumoniae* isolates (Lanes 1--5 and 7--12). Lane 6, DNA molecular weight marker (100 bp, Fermentas).](bjm-44-849-g002){#f2-bjm-44-849}

###### 

Association between antimicrobial susceptibility and integron carriage in 50 extended-spectrum β-lactamase producing clinical isolates of *Klebsiella pneumoniae*.

  Antibiotic                Integron positive isolates (n= 23)   Integron negative isolates (n=27)   Level of significance[\*](#tfn2-bjm-44-849){ref-type="table-fn"}                        
  ------------------------- ------------------------------------ ----------------------------------- ------------------------------------------------------------------ ------ ------ ------ -------------------------------------------------
  Kanamycin                 91.4                                 4.3                                 4.3                                                                48.2   40.7   11.1   [\*\*](#tfn3-bjm-44-849){ref-type="table-fn"}
  Tobramycin                82.6                                 0                                   17.4                                                               51.9   0      48.1   [\*](#tfn2-bjm-44-849){ref-type="table-fn"}
  Gentamicin                47.8                                 13                                  39.2                                                               25.9   11.1   63     NS
  Norfloxacin               65.3                                 4.3                                 30.4                                                               33.3   22.3   44.4   NS
  Aztreonam                 95.7                                 4.3                                 0                                                                  44.4   11.2   44.4   [\*\*\*](#tfn4-bjm-44-849){ref-type="table-fn"}
  Cefotaxime                91.4                                 4.3                                 4.3                                                                48.1   3.8    48.1   [\*\*\*](#tfn4-bjm-44-849){ref-type="table-fn"}
  Ceftazidime               87                                   8.7                                 4.3                                                                44.4   22.3   33.3   [\*\*](#tfn3-bjm-44-849){ref-type="table-fn"}
  Cefepime                  65.3                                 4.3                                 30.4                                                               40.7   0      59.3   NS
  Spectinomycin             69.6                                 26.1                                4.3                                                                44.4   40.7   14.9   NS
  Piperacillin              100                                  0                                   0                                                                  100    0      0      NS
  Piperacillin/Tazobactam   26.1                                 34.8                                39.1                                                               14.8   29.6   55.6   NS
  Streptomycin              0                                    30.4                                69.6                                                               18.5   48.2   33.3   [\*\*](#tfn3-bjm-44-849){ref-type="table-fn"}
  Ampicilin/sulbactam       73.9                                 13.1                                13                                                                 48.2   18.5   33.3   NS
  Colistin                  13                                   0                                   87                                                                 14.8   0      85.2   NS
  Amikacin                  17.4                                 34.8                                47.8                                                               25.9   3.7    70.4   NS
  Nitrofurantoin            8.7                                  26.1                                65.2                                                               37     26     37     [\*](#tfn2-bjm-44-849){ref-type="table-fn"}
  Imipenem                  0                                    0                                   100                                                                0      0      100    NS
  Amoxyclav                 100                                  0                                   0                                                                  92.6   0      7.4    NS

The significance level was determined using the two-tailed Mann-Whitney U test.
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0.1% level.

NS, non-significant; R, resistant; I, intermediately resistant; S, sensitive.

###### 

Distribution of variable region fragments sizes among class1 integron carrying ESBL producing *K. pneumoniae* clinical isolates.

  No. of isolates   No. of bands   Band size (bp)    Antibiotic resistance profiles
  ----------------- -------------- ----------------- ----------------------------------------------------------------
  2                 1              750               ATM, CAZ, AMC, CTX, KM, CPM, NOR, AS, PIP, TN
  1                 1              1000              CTX, PIP
  1                 1              1300              ATM, CAZ, AMC, CTX, KM, AK, NF, SP, NOR, AS, CL, PIP, TN
  8                 2              750--2000         ATM, CAZ, AMC, CTX, KM, CPM, SP, PIP
  4                 2              750--1000         ATM, CAZ, AMC, KM, CPM, SP, PIP
  1                 2              1300--1800        ATM, CAZ, AMC, CTX, SM, SP, NOR, AS, PIP, TN
  1                 2              750--1800         ATM, AMC, CTX, KM, GM, CPM, NOR, SP, AS, TN
  1                 2              750--2500         ATM, CAZ, AMC, CTX, GM, KM, CPM, PZT, SM, SP, NOR, AS, PIP, TN
  1                 3              500--750--1000    CAZ, CTX, KM, PIP, A/S
  1                 3              750--1000--1300   ATM, CAZ, AMC, CTX, GM, KM, CPM, SM, SP, NOR, AS, PIP, TN
  1                 3              250--1000--1700   CAZ, AMC, CTX, KM, CPM, AK, PZT, SM, SP, NOR, AS, CL, PIP, TN

Amikacin (AK), Gentamicin (GM), Kanamycin (KM), Imipenem (IPM), Aztreonam (ATM), Amoxyclav (AMC). Cefotaxime (CTX), Ceftazidime (CAZ), Cefepime (CPM), Piperacillin (PRL), Piperacillin/Tazobactam (PZT), Ampicilin/sulbactam (AS), Streptomycin (SM), Spectinomycin (SP), Tobramycin (TN), Colistin (CL), Nitrofurantoin (NF), Norfloxacin (NOR).
